Founder, CEO and Chairman of the Board of Atea Pharmaceuticals, Inc. (2012-present) Founder, CEO and Chairman of the Board of Idenix Pharmaceuticals, Inc. (1998-2010), a biopharmaceutical company which focused on the discovery, development and commercialization of antiviral therapeutics Co-Founder of Pharmasset, Inc. (1998), a biopharmaceutical company which focused on the discovery and development of antiviral therapeutics Medical/ academic appointments (1982-2000), including: o Tenured Scientist, INSERM (French eq. of NIH) (1982-1985) o Associate Scientist, Comprehensive Cancer Center, University of Alabama (1985-1989) o Associate Professor, Pharmacology, University of Alabama at Birmingham School of Medicine (1985-1989) o Director, AIDS Pharmacology Program, University of Alabama at Birmingham School of Medicine (1989-1992) o Professor, Department of Pharmacology and Senior Scientist, University of Alabama at Birmingham School of Medicine (1992-2000) o Assoc. Director, Center of AIDS Research, University of Alabama at Birmingham School of Medicine (1997-2000) Other Public Company Directorships (past five years): Kezar Life Sciences, Inc. (Chair) (Ticker: KZR), 2015-2022 ABG Acquisition Corporation (Ticker: ABGI), 2021-2023 Core Skills Drug Development / Scientific Experience Life Sciences / Healthcare Industry Business Development / Strategic Partnerships Finance & Audit M&A / Strategic Investments Senior Executive Role Corporate Governance Education University of Nice (France), Baccalauréat Faculty of Pharmacy, Marseille, PharmD Faculty of Pharmacy, Marseille, Advanced Studies Diploma in Pharmacokinetics and Biodisponibility Faculty of Pharmacy, Marseille, PhD Post-doctoral Fellow at the National Cancer Institute and Medical College of Virginia Qualifications and Expertise Provided to Our Board As Founder, CEO, and Chairman, Dr. Sommadossi provides indispensable leadership and unparalleled foundational knowledge of Atea s strategy and operations, backed by his proven success in previously founding other antiviral drug companies, including Idenix Pharmaceuticals, which he also led as CEO and Chair, and Pharmasset, each of which were later acquired. Dr. Sommadossi s deep scientific background as a Professor of Pharmacology at the University of Alabama at Birmingham School of Medicine and the author of more than 155 U.S. issued patents and more than 160 publications in peer reviewed journals further anchors Atea s scientific direction, providing the Board with expert insight crucial for overseeing research and development strategy and operational execution in the complex field of antiviral therapies.